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Everolimus: Preliminary Data on Cancer and Skin Cancers
MD Colombo
Marchesi di Inzago Hospital, Bergamo, Italy
Everolimus (Certicans) is a immunosuppressive and anti-proliferative macrolide
derived from rapamycin (sirolimus). At intracellular level, everolimus and sirolimus
are signal-trasduction inhibitors, that bind to the FKPB-12, and the resulting
complex binds and inhibits the FRAP protein (m-TOR). Its inactivation inhibits the
phosphorylation of kinase p70-S6k, thus impeding the cell growth and proliferation
and arresting the passage of the cells from the G1 to the S phase. In vitro studies
have shown that everolimus can inhibit the proliferation of numerous tumor cell
lines and that is associated with prolonged (96-120 hours) inactivation of p70-S6k
in tumor cells, even after wash-out of everolimus from the culture medium. Exactly
what molecular determinants predict responsiveness of tumor cells to rapamycin
and its derivatives is still unclear. The mTOR kinase is postulated to be downstream
of the PI-3 kinase-Akt pathway, a signalling module known to be heavily
deregulated in many human cancers. Molecular analysis has revealed that relative
sensitivity to everolimus in vitro correlates in many cases with the degree of
activation of Akt/PKB protein kinase pathway and in some cases with PTEN status.
In vivo studies in animal models, have shown that everolimus, administered as a
single oral dose, can inhibit p70 activity in tumors and skin. When the incidence of
skin cancer was studied in transplant patients, the rapamycins significantly reduced
the risk, even in the presence of cyclosporine. Clinical studies testing the potential
antineoplastic effects of rapamycines in transplant recipients are in progress or are
being initiated.
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Increased Incidence of Melanoma in Renal Transplant Recipients
B Imko-Walczuk*, LLe Mire, K Hollowood, D Gray, C Bordea, A Lally and F
Wojnarowska
*Clinical Department of Plastic Surgery and Burns Treatment at Medical University
of Gdansk, Poland and Dermatology Department in Bydgoszcz, Poland and Oxford
Radcliffe Hospital, Oxford, UK
Background: With the advent of effective immunosuppression, kidney transplanta-
tion has become an established and successful mode of treating end-stage renal
disease. Immunosuppressed renal transplant recipients have an increased risk of
diverse range of malignancies, of which non-melanoma skin cancers are the most
frequent, in particular squamous cell carcinomas (SCC). Less extensively reviewed
in the literature is the increased incidence of malignant melanoma. Objectives: To
determine the incidence and characteristic of malignant melanoma in renal
transplant recipients. Methods: We reviewed the case notes and pathology of all
patients who developed melanoma within the Oxford Transplant Unit. The clinical
details were recorded including date of transplant, immunosuppresive therapy,
interval between melanoma and transplant, site of occurrence, type of clinical and
histopathological diagnosis of melanomas and prognostic factors. Results: 15
patients developed 18 melanomas from a population of 1874 transplanted patients.
The total number of transplant years was 11942.2. The incidence of melanoma in
our population was 18/11942.2 transplant years, which is approximately 8 times
greater than the standardised rate for this region. We found that the average interval
between transplant and melanoma wasB11 years (median 8.5 years). Melanomas
occurred on the trunk in the majority of cases (58%), followed by the upper limb
(25%). All patients apart from 1 are alive with no recurrence of their melanoma.
The mean follow-up period post melanoma was 3.7 years. In all patients apart from
the patient that died, the melanomas were less than 1 mm Breslow thickness. That
patient’s melanoma was 4.5 mm thick. In the cases in vertical growth phase (VGP)
the tumour infiltrating lymphocyte (TIL) response was absent in 4 cases and non
brisk in 1 patient. Conclusion: In the Oxford transplant population studied
melanomas occurred at approximately 8 times the rate of the general population.
This is the largest increase in rate described in the literature. The patients had better
outcome than would have been expected from series previously published. We feel
that this was due to the fact that they were mostly detected at a relatively early
stage. Renal transplant patients have dedicated dermatology clinics in Oxford,
which may have contributed to the early diagnosis and good outcome. There is a
necessity to set up regular Clinics for organ transplant recipients (OTR) in Poland.
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Skin Cancers in Patients with HIV Disease in Romagna, Italy
D Calista
Dermatology Unit, ‘‘M. Bufalini’’ Hospital, Cesena, Italy
Background: During the last decade antiretroviral therapies have greatly changed
the course of HIV disease, improving the life expectation of HIVþ subjects.
However, the dark sides of this success are the complications of a lifelong
immunosuppression and an increased risk of cancer. Objective: The current study
was conducted in order to elucidate the spectrum of skin cancers in a population of
HIV positive patients over a period of 10 years. Patients and methods: a
retrospective chart review was performed on 2,012 subjects with HIV disease
living in Romagna, in the North-East of Italy, who had been diagnosed with
primitive skin cancers, excuding Kaposi’s sarcoma, between January 1994 and June
2004. The data collected included the patient’s age when the skin tumour was
diagnosed, gender, location of the neoplasms, its pathologic findings, clinical
outcome, length of immunosuppression, stage of HIV disease, viremia and CD4þ
cell counts at the moment of skin cancer diagnosis, predisposing risk factors for
AIDS. Results: data from 24 patients (with a total of 29 skin cancers) were included.
Nine Basal Cell Carcinoma (BCC) were diagnosed in 7 patients; 8 Squamous Cell
Carcinoma (SCC) in 6; Cutaneous Malignant Melanoma (CMM) in 7; Bowen’s
Disease (BD) in 2; and Erythroplasia of Queyrat (EQ) was detected in a subject. The
BCC/ SCC (both in situ and invasive) ratio in our patients was 0.18. Conclusions: in
our population HIVþ subjects seem to be more prone of developing SCC, HIVþ
homosexuals appeared to be higher risk patients for CMM in comparison with
people that become HIVþ through heterosexual or drug addiction behaviours. The
clinical outcome for skin cancer in our patients did not appear worst than that
observed in HIV- immunocompetent population.
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Skin Neoplasms in Ethiopia
S Trincone, R Calcaterra, V Padovese, M Terranova, G Franco, M Valenzano, R
Fazio and A Morrone
Department of Preventive Medicine for Migration, Tourism and Tropical
Dermatology, San Gallicano Institute, Rome, Italy
Skin cancer in dark-skinned African people is believed to be infrequent, but there
are very little data available concerning the actual prevalence and incidence of skin
cancer and melanoma in this population. Some authors reported an incidence of
skin cancer in 1–2% of people of African descent (i.e. dark-skinned people)
worldwide (1). Unlike among people of European descent, for whom basal cell
carcinoma (BCC) is most common, squamous cell carcinoma (SCC) is the most
frequent type of skin cancer among dark-skinned people, making up 60% of all
cases of skin neoplasm (2). Melanoma is considered very rare amongst dark-
skinned people; the most common type is acral lentiginous. Despite its rarity in the
aforementioned population, however, it is still possible to witness the malignant
evolution of a pre-existent nevus. This occurs in about one out of every two
thousand cases. In our opinion, the aforementioned figures are underestimated;
much of this population, particularly those living in Africa, does not have access to
dermatological specialists, which may result in the under-diagnosis of melanoma
and other skin cancers. On January 2005 a dermatological hospital named Italian
Dermatological Hospital (IDH) has been opened in Quiha`, a village near Mekele,
the capital city of Tigray Region in Ethiopia. San Gallicano Institute and IISMAS
(International Institute of Medical, Anthropological and Social Sciences) in
collaboration with Tigray Regional Health Bureau and Mekele Civil Hospital have
started the medical activity. We present the cases of skin cancer and melanoma that





Is Skin Cancer Screening Worthwhile in a Working Population?
TK Eigentler, B Weide, U Leiter, A Kamin and C Garbe
Department of Dermatology, University of Tu¨bingen, Germany
Background: Over the last decades the incidence of skin cancer continuously
increased in the Caucasian population. Early diagnosis and adequate therapy can
lead to complete cure. Therefore skin cancer screening programmes seem to be
reasonable. Methods: Employees of an insurance company where asked to
complete a self-assessment questionnaire regarding their sun behaviours (tanning
ability, sunburns in childhood and adolescence, regular holidays in sunny climates,
usage of sun beds), number and size (4.5 cm) of melanocytic nevi, former
immunosuppression or chemotherapy and history of skin cancer. Afterwards a total
body nevi count, an evaluation of the skin type as well as an assessment of
pigmentary and UV-induced features were performed by trained dermatologists. A
risk-dependant follow up schedule (casual self-assessment, regular self-assessment,
and constant assessment by a specialist) according to the total number of nevi,
existence and number of atypical nevi, skin type, and history of skin cancer was
recommended for each employee individually. Results: 722 employees (male 49%,
female 51%, age: 40721.06 y) were evaluated. Most employees underestimated
their total number of nevi (0-10 n.: 15.5% self. vs. 13.4% expert; 11-30 n.: 31.8%
self. vs. 35.1% expert; 31-50 n.: 26.5% self vs. 24% expert; 51-100 n.: 19.7% self
vs. 15.9% expert; 100þ n.: 6.6% self. vs. 16.5% expert). 62.2% were judged as
low-risk, 26.6% as intermediate risk and 11.2% as high risk patients. 27 employees
(3.7%) with suspicious lesions were transferred to the clinics for further evaluation.
Conclusion: Skin cancer screening in a working population seems to be reasonable.
Approximately every 10th employee was judged as high risk patient and
encouraged to participate in a regular follow-up scheme.
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Knowledge of Melanoma and Attitude Towards Moles in Italian
Melanoma Patients
P Amerio, D Abeni$, MC Fargnoli#, M Auriemma, F Formicone#, F Sampogna$, G
Proietto, R Capizzi*, C Feliciani*, S Tabolli$, K Peris# and A Tulli
Department of Dermatology, University G. D’Annunzio, Chieti-Pescara, Italy,
#Department of Dermatology, University of L’Aquila, Italy, $Dermatologic Services,
Istituto Dermopatico dell’Immacolata, IRCCS, Rome, Italy and *Department of
Dermatology, Catholic University of the Sacred Heart, Rome, Italy
Strategies aimed at improving early detection of melanoma are mainly based on the
education of the population about criteria for recognizing suspicious skin lesions,
on the rapid referral to dermatology centres and on regular dermatological visits in
high risk patients. Our intent to assess the habits, knowledge of risk factors and
attitude towards melanoma and correlate it with clinical features in melanoma
patients from a population, such the Italian, that could acknowledged as a
population not formally informed about melanoma. All the patients attending the
departments of dermatology in Chieti, L’Aquila and Rome with the diagnosis of
melanoma in the years 2004 and 2005 were given a questionnaire concerning their
knowledge of melanoma risk factors, early detection melanoma rules (ABCD), on
who prompted their referral to the excision of the melanoma and on the most
important media sources of information on melanoma. Two hundred and ten
questionnaire were given but only 160 patients returned it. Subtle changes in the
colour, but not other features of the ABCD rule, was more frequently associated
with thin melanomas (po0.008). Instead people who were referred only for gross
changes of moles such as bleeding were associated with thicker lesions (po0.002).
Self detection of melanoma did not help in the early diagnosis (po0.388). From our
data it seems that applications of the ABCD rule is one of the most important
features that can help in the early diagnosis of melanoma; moreover all the other
information gathered may be useful to define educational strategies in the future.
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Cellular Retinol Binding Protein-1 Expression in Normal Skin and
Cutaneous Tumors
A Orlandi1, A Ferlosio1, C Angeloni1, A Francesconi1, L Bianchi2 and LG Spagnoli1
1Department of Anatomic Pathology and 2Department of Dermatology, University
of Rome Tor Vergata, Rome, Italy
Retinoids have important roles in growth and differentiation of epidermal cells.
Cellular retinol binding protein 1 (CRBP-1) is a 15,000 Da cytosolic chaperone-like
molecule regulating the pre-nuclear phase of retinoid signaling. CRBP-1 expression
also influences the uptake and subsequent esterification of retinol and its
intracellular bioavailability. We analyzed the expression of CRBP-1 in normal
and abnormal epidermal differentiation, actinic keratosis and squamous and basal
cell carcinomas by immunohistochemistry using a rabbit polyclonal antibody.
CRBP-1 immunodetection was low in the basal layer of normal epidermis, with
increased expression in granular layer keratinocytes; CRBP-1 was completely
absent in the corneum. CRBP-1 expression was strong in normal adnexa. In
psoriatic lesions, a hyperproliferative condition of the skin, an increased epidermal
expression of CRBP-1 was also observed. In basal cell carcinomas, CRBP-1
expression was low or almost absent in classical nodular or superficial lesions,
except in the keratotic variant of the tumor. Increased expression of CRBP-1 was
present in actinic keratosis and well-differentiated squamous cell carcinomas,
whereas it was reduced in less differentiated tumors. Investigation of mechanisms
CRBP-1 expression in epidermal cells may help to understand the physiopatho-
logical changes, which occur in keratinocytes during hyperproliferative and
oncogenetic processes and better address possible adjuvant retinoid therapy.
CRBP-1 immunodetection can also be applied as an adjuvant marker of
keratinocyte differentiation.
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Pegylated Interferon Alfa-2b and Temozolomide for Advanced Meta-
static Melanoma (Stage IV AJCC). A Multicenter Phase II Trial of the
Dermatologic Cooperative Oncology Group (DeCOG)
K Spieth, R Dummer, U Leiter, C Garbe, J Gille, JC Becker, A Hauschild, W Tilgen,
R Kaufmann and D Schadendorf
Dept. of Dermatology, University Hospital of Frankfurt, Germany; Zu¨rich,
Switzerland; Tu¨bingen, Germany; Wu¨rzburg, Germany; Kiel, Germany; Saarland,
Germany; Mannheim, Germany
Modifying the pharmacokinetic profile of IFN alfa-2b (PegIFN) may improve its
activity and tolerability. The DeCOG evaluated the combination of temozolomide
(TMZ) with pegylated interferon alfa-2b (PegIFN) in stage IV metastatic melanoma
in an open-label, phase II trial at 10 study sites. Eligible patients with histologically
confirmed metastatic melanoma were between 18 and 75 years, had a Karnofsky
score of 4 60%, no brain metastases and no prior chemotherapy. The regimen (28
d cycles) consisted of TMZ (200 mg/m2 d 1-5) in combination with PegIFN (100 mg
s.c. d 1, 8, 15 and 21). OR and OS were primary and TTP and toxicity were
secondary endpoints. 124 patients were accrued, 116 individuals were treated per
protocol. At the time of data analysis, 81.0% had died from melanoma and median
follow up time was 9.4 months. OR was 18.1% (2 CR, 1.7%; 16 PR; 16.4%); 25.0%
of patients presented with SD and 54.3 % progressed (2.6% not evaluable). Median
TTP was 2.8 months, median 4 OS 9.0 months (95% CI 7,4;10,6). Grade (gr) 3/4
leucopenia occurred in 22.8% and gr 3/4 thrombocytopenia in 20.3%. Severe (gr 3/
4) nausea was rare (1.7%). Liver enzyme elevation occurred in 30.5 % (26.3% gr 1/
2; 4.2% gr 3). Combination therapy with TMZ and pegylated interferon alfa-2b
constitutes a manageable treatment option in the outpatient setting for advanced
metastatic melanoma. Its primary advantage is an increased patient convenience as
a result of oral intake of TMZ and once weekly application of PegIFN.
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Melanoma-Associated Chondroitin Sulfate Proteoglycan (MCSP): A
Promising Target Antigen for Cancer Immunotherapy?
C Erfurt*, C Heirmany, K Thielemansy, S Zhaojun#, P van der Bruggen#, G Schuler*,
ES Schultzþ
*Department of Dermatology, University Hospital of Erlangen, Erlangen, Germany,
yLaboratory of Physiology, Medical School, Free University of Brussels, Brussels,
Belgium, #Ludwig Institute for Cancer Research, Brussels, Belgium and
þDepartment of Dermatology and Allergology, University Hospital Giessen and
Marburg, Marburg, Germany
The identification of tumour antigens recognized by T cells on human tumour cells
has opened new avenues in cancer immunotherapy. Unfortunately, clinical
responses in most studies have been observed only in the minority of vaccinated
patients. There are several possible reasons for these disappointing results. First,
tumour cells can downregulate antigen expression as most antigens identified so far
do not play an essential functional role for their malignant phenotype. Second,
tumour cells can downregulate or loose the expression of HLA molecules and thus
escape recognition by T cells. Third, tolerance avoids the induction of potent and
high-affinity T cell responses as most antigens used in tumour immunotherapy
represent self antigens. An ideal target antigen, therefore, would be tumour-specific
and functional relevant for the tumour. MCSP represents a transmembrane
glycoprotein-proteoglycan complex, consisting of a N-linked glycoprotein of about
250 kDa and a 4 450 kDa proteoglycan component and is expressed in 4 90% of
human melanoma tissues. MCSP was found to be involved in signal cascades
concerning adhesion and extravasation of tumor cells and therefore thought to play
an important role in determining the invasive and metastatic potential of melanoma
cells. However, MCSP has been shown to be expressed in some normal tissues and
thus tolerance or autoimmunity (when breaking tolerance) could be a major
drawback also with this antigen. Surprisingly, we could rapidly generate MCSP-
specific T cell clones from healthy blood donors by the use of antigen-loaded
dendritic cells and identify several T cell epitopes within the core protein of MCSP.
The isolated T cells directly recognized MCSP-expressing melanoma cells.
Furthermore, we could demonstrate by ELISPOT analysis a strong MCSP-specific
T cell immunity in the peripheral blood of the majority of healthy donors tested and
these donors showed no clinical signs of autoimmunity. Melanoma patients also
showed MCSP-specific T cell reactivity but clearly to a lesser extent than normal
donors. This T cell reactivity seemed to decrease upon tumour progression. Our
findings are interesting as they not only provide us with new potential target
antigens for tumour immunotherapy but in addition they give new challenging
insights in the concept of self tolerance and autoimmunity.
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